al- Nahj al-qawīm hadīyah li-man talaqqāhā bi-qalb salīm : manuscript, [ca. 1900]

The text starts with a praise of the Sultan Abdülhamid and his governor Osman Nuri Paşa. Then it discusses the necessity of obedience to the Sultan and the authorities from a religious point of view. It then touches briefly on several ethical issues. The text may or may not be complete at the end.

[Calligraphic specimen, 1205?, i.e. 1790 or 1791?].

Exquisite album of calligraphy (muraqqaʻ or murakkaa) with design for a monumental inscription to appear in stone on a commemorative range marker (menzil taşı) of Bilâl Ağa (d.1807?), likely executed by Yesari Mehmed Esad Efendi (d.1798), the great Ottoman master of nastaʻlīq (talik).

Koran : manuscript, [1887 or 8].

Illumination on pp. [1-2]; chapter headings illuminated; gold dots and foliate flourishes mark verse and chapter endings; text enclosed in wide gold borders; illuminated marginal rosettes mark division of text into thirtieths (juzʼ) and sixtieths (ḥizb); gilder's name at bottom of p. [522]: dhahhabahu Bahāʼ al-Dīn bin Tawfīq; edges gilded with foliate patterns; green leather endpages painted with gold and silver sunburst designs; binding gold-stamped and painted in silver and gold foliate designs.

[Calligraphic specimen, 1206, i.e. 1791 or 1792].

Exquisite album of calligraphy (muraqqaʻ / murakkaa) employing ḥadīth of the Prophet executed by the celebrated Ottoman calligrapher Mahmud Celâleddin Efendi (d.1829) in imitation of a model executed by the master calligrapher Hafız Osman Efendi (d.1698).

[Calligraphic specimen, early to mid 18th century].

Exquisite album of calligraphy (muraqqaʻ or murakkaa) comprising kıt'alar employing ḥadīth of the Prophet executed by the celebrated Ottoman calligrapher Eğrikapılı Mehmet Râsim Efendi (d.1756), renowned student of Seyyid Abdullah of Yedikule (d.1731).

[al-Kawākib al-durrīyah fī madḥ khayr al-barīyah, 16th century?].

Fine copy of al-Būṣīrī's poem in praise of the Prophet accompanied by elucidation in Persian and Turkish.

al-Asmāʼ al-ḥusná mustakhrajah min al-Qurʼān al-ʻaẓīm wa-Kitāb al-Ṭibb al-nabawī, [15th century?].

A work on prophetic medicine (or the Prophet's medicine) by al-Maqdisī (d.1245) preceded by a short treatise of uncertain authorship on the beautiful names of God.

Nazm-ı Dilârâ, [1231, i.e. 1815 or 1816].

Elegant autograph copy of the versified Persian-Turkish glossary of the müderris Osman Şakir (whose name appears in Īḍāḥ al-maknūn as ʻUthmān Shukrī, d.1818?). Apparently inspired by the popular Tuhfe-yi Vehbî (used for many years in Ottoman schools) of Sünbülzâde Vehbi Mehmet Efendi (d.1809), see opening matter on p.5-15.

Hāẕā Kitāb-i Khvājah Ḥāfiẓ-i Shīrāzī, [1280, i.e. 1863 or 1864].

Richly elegant copy of the Dīvān of the masterful poet Ḥāfiẓ (Khvājah Shams al-Dīn Muḥammad Shīrāzī, d.1390?).

Koran : manuscript, [1892-1896].

marginal notes/ examined by M. Zacharia 8/24/89."

Ḥilyat al-ʻaṣr al-jadīd fī shamāʼil al-malik al-ḥamīd [microform] /

Microfilm.

The city of the sultan, and domestic manners of the Turks in 1836 [microform] /

Mode of access: Internet.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment : the M77001 study group

Purpose: This randomized, multicenter trial compared first-line trastuzumab plus docetaxel versus docetaxel alone in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Patients and Methods: Patients were randomly assigned to six cycles of docetaxel 100 mg/m 2 every 3 weeks, with or without trastuzumab 4 mg/kg loading dose followed by 2 mg/kg weekly until disease progression. Results: A total of 186 patients received at least one dose of the study drug. Trastuzumab plus docetaxel was significantly superior to docetaxel alone in terms of overall response rate (61% v 34%; P = .0002), overall survival (median, 31.2 v 22.7 months; P = .0325), time to disease progression (median, 11.7 v 6.1 months; P = .0001), time to treatment failure (median, 9.8 v 5.3 months; P = .0001), and duration of response (median, 11.7 v 5.7 months; P = .009). There was little difference in the number and severity of adverse events between the arms. Grade 3 to 4 neutropenia was seen more commonly with the combination (32%) than with docetaxel alone (22%), and there was a slightly higher incidence of febrile neutropenia in the combination arm (23% v 17%). One patient in the combination arm experienced symptomatic heart failure (1%). Another patient experienced symptomatic heart failure 5 months after discontinuation of trastuzumab because of disease progression, while being treated with an investigational anthracycline for 4 months. Conclusion: Trastuzumab combined with docetaxel is superior to docetaxel alone as first-line treatment of patients with HER2-positive MBC in terms of overall survival, response rate, response duration, time to progression, and time to treatment failure, with little additional toxicity. © 2005 by American Society of Clinical Oncology.

A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma

Background: Hydroxyurea (HU), an inhibitor of ribonucleotide reductase, may potentiate the activity of 5-fluorouracil (5-FU) and folinic acid (FA) by reducing the deoxyribonucleotide pool available for DNA synthesis and repair. However as HU may inhibit the formation of 5-fluoro-2-deoxyuridine-5- monophosphate (FdUMP), one of the principal active metabolites of 5-FU, the scheduling of HU may be critical. In vitro experiments suggest that administration of HU following 5-FU, maintaining the concentration in the region of I mM for six or more hours, significantly enhances the efficacy of 5-FU. Patients and methods: 5-FU/FA was given as follows: days 1 and 2 - FA 250 mg/m 2 (max. 350 mg) over two hours followed by 5-FU 400 mg/m 2 by intravenous bolus (ivb) over 15 minutes and subsequently 5-FU 400 mg/m 2 infusion (ivi) over 22 hours. HU was administered on day 3 immediately after the 5-FU with 3 g ivb over 15 minutes followed by 12 g ivi over 12 hours. Results: Thirty patients were entered into the study. Median survival was nine months (range 1-51 + months). There were eight partial responses (28%, 95% CI: 13%-47%). The median duration of response was 6.5 (range 4-9 months). Grade 3-4 toxicities included neutropenia (grade 3 in eight patients and grade 4 in five), anaemia (grade 3 in one patient) and diarrhoea (grade 3 in two patients). Neutropenia was associated with pyrexia in two patients. Phlebitis at the infusion site occurred in five patients. The treatment was complicated by pulmonary embolism in one patient and deep venous thrombosis in another. Conclusion: HU administered in this schedule is well tolerated. Based on these results and those of other phase II studies, a randomised phase III study of 5-FU, FA and HU versus 5-FU and FA using the standard de Gramont schedule is recommended.

Aspects of tautomerism. Part II. Reactions of the pseudo-acid chloride of o-benzoylbenzoic acid with nucleophiles

Reactions of fourteen nucleophiles with the pseudo-acid chloride of o-benzoylbenzoic acid in two solvents have been studied. The nucleophiles that react primarily at the tetrahedral carbon atom to give pseudo derivatives, are weaker than those that react at the carbonyl carbon atom causing opening of the lactone ring. An explanation for this phenomenon is advanced.